Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$46.13 USD
+1.33 (2.97%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $46.14 +0.01 (0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth D Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Supernus Pharmaceuticals, Inc. has a market cap of $2.51B, which represents its share price of $44.80 multiplied by its outstanding shares number of 56.07M. As a mid-cap company, SUPN's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SUPN 46.13 +1.33(2.97%)
Will SUPN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Biogen Gets EU Nod for First Postpartum Depression Drug
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Other News for SUPN
Is SUPN likely to continue lower? 20 Day Moving Average Resistance shows up after rising 1.84%
SUPN forms NR7 on September 16
Supernus Pharmaceuticals: Heading In The Right Direction
SUPN Fell Below 20 Day Moving Average on September 15
Top Executive Sells Thousands of Supernus Pharmaceuticals Shares!